Exelixis
EXEL
344 hedge funds and large institutions have $4.82B invested in Exelixis in 2021 Q2 according to their latest regulatory filings, with 42 funds opening new positions, 117 increasing their positions, 123 reducing their positions, and 43 closing their positions.
1.41% more ownership
Funds ownership: 84.05% → 85.46% (+1.4%)
0% more call options, than puts
Call options by funds: $20.1M | Put options by funds: $20.1M
1% less funds holding
Funds holding: 347 → 344 (-3)
2% less first-time investments, than exits
New positions opened: 42 | Existing positions closed: 43
5% less repeat investments, than reductions
Existing positions increased: 117 | Existing positions reduced: 123
18% less capital invested
Capital invested by funds: $5.9B → $4.82B (-$1.09B)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$115M |
| 2 |
JP Morgan Chase
New York
|
+$64.6M |
| 3 |
American Century Companies
Kansas City,
Missouri
|
+$31.2M |
| 4 |
SI
Scout Investments
Kansas City,
Missouri
|
+$20.2M |
| 5 |
Two Sigma Advisers
New York
|
+$14.7M |
Top Sellers
EXEL Hedge Fund Activity: Q2 2021 in Review
344 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Exelixis (EXEL) for Q2 2021, worth a combined $4.82B — down 18% from $5.9B a quarter earlier.
Sellers outnumbered buyers: 43 funds closed out of EXEL and 42 opened new positions — a net loss of 1 holder — while 123 trimmed existing stakes and 117 added.
The largest buyer was Fidelity Investments, adding an estimated $115M. The largest seller was T. Rowe Price Associates, cutting an estimated $24.7M.
- 344 institutional investors held Exelixis (EXEL) as of Q2 2021, down from 347 in Q1 2021.
- Funds reported $4.82B of Exelixis stock for Q2 2021, down 18% quarter-over-quarter.
- 42 funds opened new Exelixis positions in Q2 2021 and 43 closed out, a net change of -1 holder.
- The largest Exelixis buyer in Q2 2021 was Fidelity Investments, an estimated $115M added.
- The largest Exelixis seller in Q2 2021 was T. Rowe Price Associates, an estimated $24.7M sold.
Based on aggregated 13F filings for Q2 2021.